



**Second Quarter 2022
Other Financial Disclosures**

Table of Contents

Table 1: Sales by Segment	1
Table 2: Sales by Geographic Area	2
Table 3: Sales of Key Products/Franchises	3 - 8
Table 3a: Supplemental Sales Reconciliation	9
Table 4: Condensed Consolidated Statement of Earnings - QTD	10
Table 5: Condensed Consolidated Statement of Earnings - YTD	11
Table 6: Non-GAAP Adjusted Operational Sales Growth - QTD	12
Table 7: Non-GAAP Adjusted Operational Sales Growth - YTD	13
Table 8: Non-GAAP Adjusted Net Earnings	14
Table 9: Non-GAAP IBT by Segment - QTD	15
Table 10: Non-GAAP IBT by Segment - YTD	16
Table 11: Non-GAAP P&L Reconciliation	17

Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)

	SECOND QUARTER					SIX MONTHS				
	2022	2021	Total	Percent Change Operations	Currency	2022	2021	Total	Percent Change Operations	Currency
Sales to customers by segment of business										
Consumer Health ⁽¹⁾										
U.S.	\$ 1,687	1,751	(3.6) %	(3.6)	-	\$ 3,244	3,362	(3.5) %	(3.5)	-
International	2,118	2,103	0.6	7.3	(6.7)	4,147	4,133	0.3	5.7	(5.4)
	3,805	3,854	(1.3)	2.3	(3.6)	7,391	7,495	(1.4)	1.6	(3.0)
Pharmaceutical ⁽¹⁾										
U.S.	7,159	6,869	4.2	4.2	-	13,791	13,315	3.6	3.6	-
International	6,158	5,611	9.8	22.1	(12.3)	12,395	11,266	10.0	19.4	(9.4)
	13,317	12,480	6.7	12.3	(5.6)	26,186	24,581	6.5	10.8	(4.3)
Pharmaceutical excluding COVID-19 Vaccine ^(1,3)										
U.S.	7,114	6,818	4.3	4.3	-	13,671	13,164	3.9	3.9	-
International	5,659	5,498	2.9	13.9	(11.0)	11,514	11,153	3.2	11.9	(8.7)
	12,773	12,316	3.7	8.6	(4.9)	25,185	24,317	3.6	7.5	(3.9)
MedTech ⁽²⁾										
U.S.	3,351	3,299	1.6	1.6	-	6,576	6,353	3.5	3.5	-
International	3,547	3,679	(3.6)	5.1	(8.7)	7,293	7,204	1.2	8.0	(6.8)
	6,898	6,978	(1.1)	3.4	(4.5)	13,869	13,557	2.3	5.9	(3.6)
U.S.	12,197	11,919	2.3	2.3	-	23,611	23,030	2.5	2.5	-
International	11,823	11,393	3.8	13.9	(10.1)	23,835	22,603	5.5	13.3	(7.8)
Worldwide	24,020	23,312	3.0	8.0	(5.0)	47,446	45,633	4.0	7.8	(3.8)
U.S.	12,152	11,868	2.4	2.4	-	23,491	22,879	2.7	2.7	-
International	11,324	11,280	0.4	9.8	(9.4)	22,954	22,490	2.1	9.5	(7.4)
Worldwide excluding COVID-19 Vaccine ⁽³⁾	\$ 23,476	23,148	1.4 %	6.0	(4.6)	\$ 46,445	45,369	2.4 %	6.1	(3.7)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

⁽¹⁾ Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes

⁽²⁾ Previously referred to as Medical Devices

⁽³⁾ Refer to supplemental sales reconciliation schedule

Johnson & Johnson and Subsidiaries

Supplementary Sales Data

(Unaudited; Dollars in Millions)

	SECOND QUARTER				
	2022	2021	Percent Change		
			Total	Operations	Currency
Sales to customers by geographic area					
U.S.	\$ 12,197	11,919	2.3 %	2.3	-
Europe	6,085	5,668	7.3	20.7	(13.4)
Western Hemisphere excluding U.S.	1,536	1,367	12.4	14.9	(2.5)
Asia-Pacific, Africa	4,202	4,358	(3.6)	4.7	(8.3)
International	11,823	11,393	3.8	13.9	(10.1)
Worldwide	\$ 24,020	23,312	3.0 %	8.0	(5.0)

	SIX MONTHS				
	2022	2021	Percent Change		
			Total	Operations	Currency
U.S.	\$ 23,611	23,030	2.5 %	2.5	-
Europe	12,109	11,082	9.3	20.1	(10.8)
Western Hemisphere excluding U.S.	3,018	2,791	8.1	9.9	(1.8)
Asia-Pacific, Africa	8,708	8,730	(0.2)	5.6	(5.8)
International	23,835	22,603	5.5	13.3	(7.8)
Worldwide	\$ 47,446	45,633	4.0 %	7.8	(3.8)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	SECOND QUARTER				
	2022	2021	% Change		
			Reported	Operational ⁽¹⁾	Currency
CONSUMER HEALTH SEGMENT ^(2,3)					
OTC					
US	\$ 663	675	-1.8%	-1.8%	-
Intl	818	752	8.8%	15.9%	-7.1%
WW	1,482	1,426	3.8%	7.5%	-3.7%
SKIN HEALTH / BEAUTY					
US	629	659	-4.5%	-4.5%	-
Intl	497	511	-2.8%	5.1%	-7.9%
WW	1,126	1,170	-3.7%	-0.3%	-3.4%
ORAL CARE					
US	170	165	3.4%	3.4%	-
Intl	224	260	-14.1%	-8.7%	-5.4%
WW	394	426	-7.3%	-4.0%	-3.3%
BABY CARE					
US	88	97	-9.1%	-9.1%	-
Intl	287	290	-1.0%	3.7%	-4.7%
WW	375	387	-3.1%	0.5%	-3.6%
WOMEN'S HEALTH					
US	3	3	8.9%	8.9%	-
Intl	228	227	0.1%	7.2%	-7.1%
WW	230	230	0.2%	7.2%	-7.0%
WOUND CARE / OTHER					
US	133	153	-12.7%	-12.7%	-
Intl	65	64	1.7%	5.2%	-3.5%
WW	197	216	-8.4%	-7.4%	-1.0%
TOTAL CONSUMER HEALTH					
US	1,687	1,751	-3.6%	-3.6%	-
Intl	2,118	2,103	0.6%	7.3%	-6.7%
WW	\$ 3,805	3,854	-1.3%	2.3%	-3.6%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	SIX MONTHS				
	2022	2021	% Change		
			Reported	Operational ⁽¹⁾	Currency
CONSUMER HEALTH SEGMENT ^(2,3)					
OTC					
US	\$ 1,333	1,274	4.6%	4.6%	-
Intl	1,609	1,425	12.9%	18.6%	-5.7%
WW	2,943	2,699	9.0%	12.0%	-3.0%
SKIN HEALTH / BEAUTY					
US	1,173	1,293	-9.2%	-9.2%	-
Intl	965	1,040	-7.2%	-1.1%	-6.1%
WW	2,138	2,333	-8.3%	-5.6%	-2.7%
ORAL CARE					
US	313	328	-4.6%	-4.6%	-
Intl	447	514	-13.0%	-8.6%	-4.4%
WW	760	843	-9.7%	-7.1%	-2.6%
BABY CARE					
US	173	193	-10.3%	-10.3%	-
Intl	557	583	-4.4%	-0.6%	-3.8%
WW	730	776	-5.9%	-3.0%	-2.9%
WOMEN'S HEALTH					
US	7	6	8.1%	8.1%	-
Intl	452	446	1.3%	7.7%	-6.4%
WW	458	452	1.4%	7.7%	-6.3%
WOUND CARE / OTHER					
US	245	268	-8.6%	-8.6%	-
Intl	117	125	-6.6%	-4.5%	-2.1%
WW	361	393	-8.0%	-7.3%	-0.7%
TOTAL CONSUMER HEALTH					
US	3,244	3,362	-3.5%	-3.5%	-
Intl	4,147	4,133	0.3%	5.7%	-5.4%
WW	\$ 7,391	7,495	-1.4%	1.6%	-3.0%

See footnotes at end of schedule

PHARMACEUTICAL SEGMENT ^(2,3)	REPORTED SALES vs. PRIOR PERIOD (\$MM)					REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	SECOND QUARTER					SIX MONTHS				
	2022	2021	% Change			2022	2021	% Change		
		Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency	
IMMUNOLOGY										
US	\$ 2,853	2,748	3.8%	3.8%	-	\$ 5,354	5,161	3.7%	3.7%	-
Intl	1,559	1,483	5.1%	16.2%	-11.1%	3,176	2,984	6.4%	14.9%	-8.5%
WW	4,411	4,231	4.3%	8.1%	-3.8%	8,530	8,145	4.7%	7.8%	-3.1%
REMICADE										
US	391	540	-27.4%	-27.4%	-	749	1,029	-27.1%	-27.1%	-
US Exports ⁽⁴⁾	44	93	-53.0%	-53.0%	-	124	150	-17.5%	-17.5%	-
Intl	212	255	-17.2%	-12.0%	-5.2%	437	487	-10.3%	-6.7%	-3.6%
WW	647	888	-27.2%	-25.6%	-1.6%	1,310	1,665	-21.4%	-20.3%	-1.1%
SIMPONI / SIMPONI ARIA										
US	301	290	3.8%	3.8%	-	588	545	7.9%	7.9%	-
Intl	266	294	-9.7%	0.3%	-10.0%	549	601	-8.6%	-0.8%	-7.8%
WW	566	584	-3.0%	2.0%	-5.0%	1,137	1,146	-0.8%	3.3%	-4.1%
STELARA										
US	1,731	1,496	15.7%	15.7%	-	3,110	2,827	10.0%	10.0%	-
Intl	868	778	11.6%	24.0%	-12.4%	1,777	1,595	11.4%	20.8%	-9.4%
WW	2,599	2,274	14.3%	18.6%	-4.3%	4,887	4,422	10.5%	13.9%	-3.4%
TREMFYA										
US	382	325	17.7%	17.7%	-	773	599	29.1%	29.1%	-
Intl	214	155	38.3%	54.6%	-16.3%	413	298	38.6%	51.4%	-12.8%
WW	597	479	24.4%	29.7%	-5.3%	1,187	897	32.3%	36.6%	-4.3%
OTHER IMMUNOLOGY										
US	3	5	-50.1%	-50.1%	-	9	12	-24.8%	-24.8%	-
Intl	0	1	*	*	*	0	3	*	*	*
WW	3	7	-59.2%	-59.2%	0.0%	9	15	-39.0%	-39.0%	0.0%
INFECTIOUS DISEASES										
US	415	444	-6.4%	-6.4%	-	876	956	-8.3%	-8.3%	-
Intl	901	575	56.8%	79.3%	-22.5%	1,737	1,060	63.9%	79.0%	-15.1%
WW	1,316	1,018	29.3%	42.0%	-12.7%	2,613	2,016	29.6%	37.6%	-8.0%
COVID-19 VACCINE										
US	45	51	-11.5%	-11.5%	-	120	151	-20.4%	-20.4%	-
Intl	499	113	*	*	*	881	113	*	*	*
WW	544	164	*	*	*	1,001	264	*	*	*
EDURANT / rilpivirine										
US	9	9	-1.7%	-1.7%	-	18	19	-7.4%	-7.4%	-
Intl	215	253	-14.7%	-5.4%	-9.3%	454	486	-6.5%	2.2%	-8.7%
WW	225	262	-14.3%	-5.3%	-9.0%	473	505	-6.5%	1.9%	-8.4%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA										
US	355	368	-3.4%	-3.4%	-	724	748	-3.2%	-3.2%	-
Intl	110	137	-20.2%	-10.4%	-9.8%	242	303	-20.3%	-13.4%	-6.9%
WW	464	505	-7.9%	-5.3%	-2.6%	965	1,051	-8.1%	-6.1%	-2.0%
OTHER INFECTIOUS DISEASES										
US	6	16	-62.5%	-62.5%	-	14	37	-62.5%	-62.5%	-
Intl	77	71	7.4%	10.9%	-3.5%	160	158	1.3%	5.8%	-4.5%
WW	83	88	-5.4%	-2.6%	-2.8%	174	196	-10.9%	-7.2%	-3.7%

	REPORTED SALES vs. PRIOR PERIOD (\$MM)					REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	SECOND QUARTER					SIX MONTHS				
	2022	2021	% Change			2022	2021	% Change		
		Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency	
NEUROSCIENCE										
US	896	842	6.5%	6.5%	-	1,739	1,613	7.9%	7.9%	-
Intl	837	963	-13.0%	-4.8%	-8.2%	1,735	1,906	-8.9%	-1.7%	-7.2%
WW	1,734	1,804	-3.9%	0.5%	-4.4%	3,475	3,519	-1.2%	2.7%	-3.9%
<u>CONCERTA / Methylphenidate</u>										
US	38	35	9.4%	9.4%	-	73	82	-11.3%	-11.3%	-
Intl	123	127	-2.2%	8.0%	-10.2%	245	250	-1.7%	5.8%	-7.5%
WW	161	161	0.3%	8.3%	-8.0%	318	332	-4.1%	1.5%	-5.6%
<u>INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</u>										
US	691	645	7.3%	7.3%	-	1,352	1,234	9.6%	9.6%	-
Intl	362	380	-4.6%	6.3%	-10.9%	749	756	-0.8%	8.1%	-8.9%
WW	1,054	1,024	2.9%	6.9%	-4.0%	2,102	1,989	5.7%	9.0%	-3.3%
<u>RISPERDAL CONSTA</u>										
US	65	72	-8.9%	-8.9%	-	128	139	-7.7%	-7.7%	-
Intl	60	84	-28.0%	-19.0%	-9.0%	126	173	-27.1%	-19.3%	-7.8%
WW	125	155	-19.3%	-14.4%	-4.9%	254	312	-18.4%	-14.1%	-4.3%
<u>OTHER NEUROSCIENCE</u>										
US	102	91	11.8%	11.8%	-	186	158	17.6%	17.6%	-
Intl	292	373	-21.8%	-17.2%	-4.6%	615	728	-15.5%	-10.2%	-5.3%
WW	393	464	-15.2%	-11.6%	-3.6%	800	886	-9.6%	-5.2%	-4.4%
ONCOLOGY										
US	1,679	1,462	14.9%	14.9%	-	3,261	2,839	14.9%	14.9%	-
Intl	2,362	2,073	14.0%	26.9%	-12.9%	4,731	4,266	10.9%	20.8%	-9.9%
WW	4,042	3,535	14.3%	21.9%	-7.6%	7,992	7,105	12.5%	18.4%	-5.9%
<u>DARZALEX</u>										
US	1,021	770	32.6%	32.6%	-	1,974	1,461	35.1%	35.1%	-
Intl	965	663	45.5%	61.9%	-16.4%	1,868	1,337	39.7%	52.2%	-12.5%
WW	1,986	1,433	38.6%	46.1%	-7.5%	3,842	2,798	37.3%	43.3%	-6.0%
<u>ERLEADA</u>										
US	233	193	20.6%	20.6%	-	439	364	20.4%	20.4%	-
Intl	218	109	*	*	*	412	199	*	*	*
WW	450	302	49.5%	56.9%	-7.4%	850	563	51.1%	57.2%	-6.1%
<u>IMBRUVICA</u>										
US	349	454	-23.1%	-23.1%	-	719	898	-19.9%	-19.9%	-
Intl	620	662	-6.3%	3.6%	-9.9%	1,288	1,342	-4.0%	4.1%	-8.1%
WW	970	1,116	-13.1%	-7.2%	-5.9%	2,008	2,241	-10.4%	-5.6%	-4.8%
<u>ZYTIGA / abiraterone acetate</u>										
US	19	21	-12.2%	-12.2%	-	38	71	-47.0%	-47.0%	-
Intl	486	542	-10.2%	1.5%	-11.7%	1,006	1,130	-11.0%	-2.3%	-8.7%
WW	505	563	-10.3%	0.9%	-11.2%	1,044	1,201	-13.1%	-4.9%	-8.2%
<u>OTHER ONCOLOGY</u>										
US	57	23	*	*	-	91	44	*	*	-
Intl	72	97	-25.7%	-17.3%	-8.4%	156	258	-39.4%	-34.3%	-5.1%
WW	130	120	7.5%	14.4%	-6.9%	248	302	-18.0%	-13.7%	-4.3%

	REPORTED SALES vs. PRIOR PERIOD (\$MM)					REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	SECOND QUARTER					SIX MONTHS				
	2022	2021	% Change			2022	2021	% Change		
		Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency	
<u>PULMONARY HYPERTENSION</u>										
US	560	595	-5.8%	-5.8%	-	1,132	1,168	-3.1%	-3.1%	-
Intl	284	275	2.8%	15.3%	-12.5%	563	563	-0.1%	9.6%	-9.7%
WW	843	870	-3.1%	0.9%	-4.0%	1,695	1,731	-2.1%	1.1%	-3.2%
<u>OPSUMIT</u>										
US	265	290	-8.7%	-8.7%	-	538	562	-4.3%	-4.3%	-
Intl	173	172	0.5%	13.1%	-12.6%	343	351	-2.2%	7.4%	-9.6%
WW	438	463	-5.3%	-0.6%	-4.7%	881	913	-3.5%	0.2%	-3.7%
<u>UPTRAVI</u>										
US	272	268	1.4%	1.4%	-	541	527	2.6%	2.6%	-
Intl	56	45	26.2%	38.3%	-12.1%	112	91	23.5%	33.4%	-9.9%
WW	328	313	4.9%	6.6%	-1.7%	653	618	5.7%	7.1%	-1.4%
<u>OTHER PULMONARY HYPERTENSION</u>										
US	23	36	-36.2%	-36.2%	-	53	78	-32.3%	-32.3%	-
Intl	55	59	-8.1%	4.8%	-12.9%	108	122	-11.7%	-2.0%	-9.7%
WW	78	95	-18.7%	-10.7%	-8.0%	161	200	-19.8%	-13.9%	-5.9%
<u>CARDIOVASCULAR / METABOLISM / OTHER</u>										
US	757	780	-3.0%	-3.0%	-	1,429	1,579	-9.5%	-9.5%	-
Intl	215	241	-10.9%	-3.4%	-7.5%	453	486	-6.9%	-1.2%	-5.7%
WW	972	1,021	-4.8%	-3.1%	-1.7%	1,882	2,065	-8.9%	-7.5%	-1.4%
<u>XARELTO</u>										
US	609	569	7.1%	7.1%	-	1,117	1,158	-3.5%	-3.5%	-
Intl	-	-	-	-	-	-	-	-	-	-
WW	609	569	7.1%	7.1%	-	1,117	1,158	-3.5%	-3.5%	-
<u>INVOKANA / INVOKAMET</u>										
US	55	96	-42.9%	-42.9%	-	115	183	-37.1%	-37.1%	-
Intl	65	64	2.4%	10.2%	-7.8%	133	127	4.9%	10.6%	-5.7%
WW	120	160	-24.9%	-21.8%	-3.1%	248	310	-19.9%	-17.6%	-2.3%
<u>OTHER</u>										
US	93	116	-19.5%	-19.5%	-	197	238	-17.2%	-17.2%	-
Intl	150	178	-15.6%	-8.3%	-7.3%	320	360	-11.1%	-5.4%	-5.7%
WW	243	293	-17.2%	-12.7%	-4.5%	517	598	-13.5%	-10.1%	-3.4%
<u>TOTAL PHARMACEUTICAL</u>										
US	7,159	6,869	4.2%	4.2%	-	13,791	13,315	3.6%	3.6%	-
Intl	6,158	5,611	9.8%	22.1%	-12.3%	12,395	11,266	10.0%	19.4%	-9.4%
WW	\$ 13,317	12,480	6.7%	12.3%	-5.6%	\$ 26,186	24,581	6.5%	10.8%	-4.3%

See footnotes at end of schedule

MEDTECH SEGMENT ^(2,3,5)

INTERVENTIONAL SOLUTIONS

US	\$ 525	475	10.5%	10.5%	-
Intl	525	572	-8.1%	1.0%	-9.1%
WW	1,049	1,046	0.3%	5.3%	-5.0%

ORTHOPAEDICS

US	1,338	1,323	1.1%	1.1%	-
Intl	820	904	-9.3%	-0.6%	-8.7%
WW	2,157	2,227	-3.1%	0.5%	-3.6%

HIPS

US	240	233	3.4%	3.4%	-
Intl	148	159	-6.6%	1.7%	-8.3%
WW	388	391	-0.7%	2.7%	-3.4%

KNEES

US	216	210	2.9%	2.9%	-
Intl	133	140	-4.6%	3.9%	-8.5%
WW	349	350	-0.1%	3.3%	-3.4%

TRAUMA

US	464	447	3.9%	3.9%	-
Intl	232	263	-11.8%	-1.7%	-10.1%
WW	696	710	-1.9%	1.8%	-3.7%

SPINE, SPORTS & OTHER

US	418	434	-3.7%	-3.7%	-
Intl	306	343	-10.6%	-2.5%	-8.1%
WW	724	777	-6.8%	-3.2%	-3.6%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

SECOND QUARTER					
	2022	2021	% Change		Currency
			Reported	Operational ⁽¹⁾	
	\$ 525	475	10.5%	10.5%	-
	525	572	-8.1%	1.0%	-9.1%
	1,049	1,046	0.3%	5.3%	-5.0%
	1,338	1,323	1.1%	1.1%	-
	820	904	-9.3%	-0.6%	-8.7%
	2,157	2,227	-3.1%	0.5%	-3.6%
	240	233	3.4%	3.4%	-
	148	159	-6.6%	1.7%	-8.3%
	388	391	-0.7%	2.7%	-3.4%
	216	210	2.9%	2.9%	-
	133	140	-4.6%	3.9%	-8.5%
	349	350	-0.1%	3.3%	-3.4%
	464	447	3.9%	3.9%	-
	232	263	-11.8%	-1.7%	-10.1%
	696	710	-1.9%	1.8%	-3.7%
	418	434	-3.7%	-3.7%	-
	306	343	-10.6%	-2.5%	-8.1%
	724	777	-6.8%	-3.2%	-3.6%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

SIX MONTHS					
	2022	2021	% Change		Currency
			Reported	Operational ⁽¹⁾	
	1,019	909	12.1%	12.1%	-
	1,123	1,086	3.4%	10.2%	-6.8%
	2,141	1,995	7.4%	11.1%	-3.7%
	2,627	2,572	2.1%	2.1%	-
	1,719	1,768	-2.8%	4.2%	-7.0%
	4,345	4,340	0.1%	3.0%	-2.9%
	465	442	5.2%	5.2%	-
	312	305	2.4%	9.0%	-6.6%
	777	747	4.1%	6.8%	-2.7%
	417	395	5.6%	5.6%	-
	271	272	-0.4%	6.4%	-6.8%
	688	667	3.1%	5.9%	-2.8%
	939	897	4.7%	4.7%	-
	505	545	-7.4%	0.3%	-7.7%
	1,444	1,443	0.1%	3.0%	-2.9%
	805	838	-3.9%	-3.9%	-
	630	646	-2.4%	4.2%	-6.6%
	1,436	1,484	-3.2%	-0.4%	-2.8%

	REPORTED SALES vs. PRIOR PERIOD (\$MM)					REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	SECOND QUARTER					SIX MONTHS				
	2022	2021	Reported	% Change Operational ⁽¹⁾	Currency	2022	2021	Reported	% Change Operational ⁽¹⁾	Currency
SURGERY										
US	992	1,035	-4.1%	-4.1%	-	1,913	1,933	-1.0%	-1.0%	-
Intl	1,458	1,487	-2.0%	5.9%	-7.9%	2,971	2,961	0.3%	6.2%	-5.9%
WW	2,450	2,522	-2.8%	1.8%	-4.6%	4,884	4,894	-0.2%	3.4%	-3.6%
ADVANCED										
US	454	459	-1.1%	-1.1%	-	871	864	0.8%	0.8%	-
Intl	702	708	-0.9%	6.6%	-7.5%	1,431	1,421	0.7%	6.0%	-5.3%
WW	1,156	1,168	-1.0%	3.6%	-4.6%	2,302	2,286	0.7%	4.0%	-3.3%
GENERAL										
US	538	576	-6.4%	-6.4%	-	1,042	1,069	-2.5%	-2.5%	-
Intl	756	779	-3.0%	5.3%	-8.3%	1,540	1,540	0.0%	6.5%	-6.5%
WW	1,294	1,354	-4.5%	0.3%	-4.8%	2,582	2,608	-1.0%	2.8%	-3.8%
VISION										
US	496	467	6.2%	6.2%	-	1,017	939	8.3%	8.3%	-
Intl	745	716	4.0%	13.9%	-9.9%	1,481	1,389	6.6%	15.1%	-8.5%
WW	1,241	1,183	4.9%	10.9%	-6.0%	2,498	2,328	7.3%	12.4%	-5.1%
CONTACT LENSES / OTHER										
US	374	352	6.6%	6.6%	-	774	723	7.2%	7.2%	-
Intl	519	517	0.4%	11.0%	-10.6%	1,030	1,003	2.7%	11.9%	-9.2%
WW	894	868	2.9%	9.2%	-6.3%	1,804	1,725	4.5%	9.9%	-5.4%
SURGICAL										
US	122	115	5.1%	5.1%	-	243	216	12.1%	12.1%	-
Intl	225	199	13.6%	21.5%	-7.9%	451	386	17.0%	23.5%	-6.5%
WW	347	314	10.5%	15.5%	-5.0%	694	602	15.2%	19.4%	-4.2%
TOTAL MEDTECH										
US	3,351	3,299	1.6%	1.6%	-	6,576	6,353	3.5%	3.5%	-
Intl	3,547	3,679	-3.6%	5.1%	-8.7%	7,293	7,204	1.2%	8.0%	-6.8%
WW	\$ 6,898	\$ 6,978	-1.1%	3.4%	-4.5%	\$ 13,869	\$ 13,557	2.3%	5.9%	-3.6%

Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely

* Percentage greater than 100% or not meaningful

(1) Operational growth excludes the effect of translational currency

(2) Unaudited

(3) Certain prior year amounts have been reclassified to conform to current year product disclosures

(4) Reported as U.S. sales

(5) Previously referred to as Medical Devices

Supplemental Sales Reconciliation (Unaudited)

(Dollars in Millions)

	SECOND QUARTER					SIX MONTHS				
	Percent Change					Percent Change				
	2022	2021	Total	Operations	Currency	2022	2021	Total	Operations	Currency
Pharmaceutical										
U.S.	\$ 7,159	6,869	4.2 %	4.2	-	\$ 13,791	13,315	3.6 %	3.6	-
International	6,158	5,611	9.8	22.1	(12.3)	12,395	11,266	10.0	19.4	(9.4)
Worldwide	13,317	12,480	6.7	12.3	(5.6)	26,186	24,581	6.5	10.8	(4.3)
COVID-19 Vaccine										
U.S.	45	51	(11.5)	(11.5)	-	120	151	(20.4)	(20.4)	-
International	499	113	*	*	*	881	113	*	*	*
Worldwide	544	164	*	*	*	1,001	264	*	*	*
Pharmaceutical excluding COVID-19 Vaccine										
U.S.	7,114	6,818	4.3	4.3	-	13,671	13,164	3.9	3.9	-
International	5,659	5,498	2.9	13.9	(11.0)	11,514	11,153	3.2	11.9	(8.7)
Worldwide	12,773	12,316	3.7	8.6	(4.9)	25,185	24,317	3.6	7.5	(3.9)
Worldwide										
U.S.	12,197	11,919	2.3	2.3	-	23,611	23,030	2.5	2.5	-
International	11,823	11,393	3.8	13.9	(10.1)	23,835	22,603	5.5	13.3	(7.8)
Worldwide	24,020	23,312	3.0	8.0	(5.0)	47,446	45,633	4.0	7.8	(3.8)
COVID-19 Vaccine										
U.S.	45	51	(11.5)	(11.5)	-	120	151	(20.4)	(20.4)	-
International	499	113	*	*	*	881	113	*	*	*
Worldwide	544	164	*	*	*	1,001	264	*	*	*
Worldwide										
U.S.	12,152	11,868	2.4	2.4	-	23,491	22,879	2.7	2.7	-
International	11,324	11,280	0.4	9.8	(9.4)	22,954	22,490	2.1	9.5	(7.4)
Worldwide excluding COVID-19 Vaccine	\$ 23,476	23,148	1.4 %	6.0	(4.6)	\$ 46,445	45,369	2.4 %	6.1	(3.7)

Note: Columns and rows within tables may not add due to rounding

* Percentage greater than 100% or not meaningful

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)

SECOND QUARTER

	2022		2021		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$ 24,020	100.0	\$ 23,312	100.0	3.0
Cost of products sold	7,919	33.0	7,587	32.5	4.4
Gross Profit	16,101	67.0	15,725	67.5	2.4
Selling, marketing and administrative expenses	6,226	25.9	6,073	26.1	2.5
Research and development expense	3,703	15.4	3,394	14.6	9.1
Interest (income) expense, net	(26)	(0.1)	28	0.1	
Other (income) expense, net	273	1.1	(488)	(2.1)	
Restructuring	85	0.4	56	0.2	
Earnings before provision for taxes on income	5,840	24.3	6,662	28.6	(12.3)
Provision for taxes on income	1,026	4.3	384	1.7	167.2
Net earnings	\$ 4,814	20.0	\$ 6,278	26.9	(23.3)
Net earnings per share (Diluted)	\$ 1.80		\$ 2.35		(23.4)
Average shares outstanding (Diluted)	2,667.9		2,671.6		
Effective tax rate	17.6 %		5.8 %		
Adjusted earnings before provision for taxes and net earnings ⁽¹⁾					
Earnings before provision for taxes on income	\$ 8,171	34.0	\$ 7,776	33.4	5.1
Net earnings	\$ 6,912	28.8	\$ 6,625	28.4	4.3
Net earnings per share (Diluted)	\$ 2.59		\$ 2.48		4.4
Effective tax rate	15.4 %		14.8 %		

⁽¹⁾ See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)

SIX MONTHS

	2022		2021		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$ 47,446	100.0	\$ 45,633	100.0	4.0
Cost of products sold	15,517	32.7	14,650	32.1	5.9
Gross Profit	31,929	67.3	30,983	67.9	3.1
Selling, marketing and administrative expenses	12,164	25.6	11,505	25.2	5.7
Research and development expense	7,165	15.1	6,572	14.4	9.0
In-process research and development	610	1.3	-	-	
Interest (income) expense, net	(38)	(0.1)	76	0.2	
Other (income) expense, net	171	0.4	(1,370)	(3.0)	
Restructuring	155	0.3	109	0.2	
Earnings before provision for taxes on income	11,702	24.7	14,091	30.9	(17.0)
Provision for taxes on income	1,739	3.7	1,616	3.6	7.6
Net earnings	\$ 9,963	21.0	\$ 12,475	27.3	(20.1)
Net earnings per share (Diluted)	\$ 3.73		\$ 4.67		(20.1)
Average shares outstanding (Diluted)	2,669.2		2,674.0		
Effective tax rate	14.9 %		11.5 %		
Adjusted earnings before provision for taxes and net earnings ⁽¹⁾					
Earnings before provision for taxes on income	\$ 16,389	34.5	\$ 16,067	35.2	2.0
Net earnings	\$ 14,041	29.6	\$ 13,549	29.7	3.6
Net earnings per share (Diluted)	\$ 5.26		\$ 5.07		3.7
Effective tax rate	14.3 %		15.7 %		

⁽¹⁾ See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure

Adjusted Operational Sales Growth
SECOND QUARTER 2022 ACTUAL vs. 2021 ACTUAL

	Segments			
	Consumer Health	Pharmaceutical	MedTech	Total
WW As Reported	(1.3)%	6.7%	(1.1)%	3.0%
U.S.	(3.6)%	4.2%	1.6%	2.3%
International	0.6%	9.8%	(3.6)%	3.8%
WW Currency	(3.6)	(5.6)	(4.5)	(5.0)
U.S.	-	-	-	-
International	(6.7)	(12.3)	(8.7)	(10.1)
WW Operational	2.3%	12.3%	3.4%	8.0%
U.S.	(3.6)%	4.2%	1.6%	2.3%
International	7.3%	22.1%	5.1%	13.9%
All Other Acquisitions and Divestitures	0.6	0.1	0.0	0.1
U.S.	0.2	0.2	(0.2)	0.1
International	0.8	0.1	0.2	0.3
WW Adjusted Operational	2.9%	12.4%	3.4%	8.1%
U.S.	(3.4)%	4.4%	1.4%	2.4%
International	8.1%	22.2%	5.3%	14.2%

Note: Percentages are based on actual, non-rounded figures and may not sum

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure

Adjusted Operational Sales Growth
SIX MONTHS 2022 ACTUAL vs. 2021 ACTUAL

	Segments			
	Consumer Health	Pharmaceutical	MedTech	Total
WW As Reported	(1.4)%	6.5%	2.3%	4.0%
U.S.	(3.5)%	3.6%	3.5%	2.5%
International	0.3%	10.0%	1.2%	5.5%
WW Currency	(3.0)	(4.3)	(3.6)	(3.8)
U.S.	-	-	-	-
International	(5.4)	(9.4)	(6.8)	(7.8)
WW Operational	1.6%	10.8%	5.9%	7.8%
U.S.	(3.5)%	3.6%	3.5%	2.5%
International	5.7%	19.4%	8.0%	13.3%
Skin Health / Beauty				
<i>Dr. Ci Labo - Sedona</i>	0.5			0.1
U.S.	0.0			0.0
International	0.9			0.2
All Other Acquisitions and Divestitures	0.1	0.1	0.1	0.1
U.S.	0.2	0.1	(0.1)	0.1
International	0.1	0.0	0.2	0.1
WW Adjusted Operational	2.2%	10.9%	6.0%	8.0%
U.S.	(3.3)%	3.7%	3.4%	2.6%
International	6.7%	19.4%	8.2%	13.6%

Note: Percentages are based on actual, non-rounded figures and may not sum

Johnson & Johnson and Subsidiaries

Reconciliation of Non-GAAP Financial Measures

(Dollars in Millions Except Per Share Data)	Second Quarter		Six Months Ended	
	2022	2021	2022	2021
Net Earnings, after tax- as reported	\$4,814	\$6,278	\$9,963	\$12,475
Pre-tax Adjustments				
Intangible Asset Amortization expense	1,095	1,202	2,203	2,417
Litigation related	385	(23)	385	(23)
IPR&D	-	-	610	-
Restructuring related	128	108	200	212
Acquisition, integration and divestiture related ¹	-	14	-	(524)
(Gains)/losses on securities	109	(243)	520	(208)
Medical Device Regulation ²	70	56	130	102
COVID-19 Vaccine related costs ³	276	-	276	-
Consumer Health separation costs	268	-	370	-
Other	-	-	(7)	-
Tax Adjustments				
Tax impact on special item adjustments ⁴	(313)	(135)	(706)	(248)
Consumer Health separation tax related costs	2	-	98	-
Tax legislation and other tax related	78	(632)	(1)	(654)
Adjusted Net Earnings, after tax	\$6,912	\$6,625	\$14,041	\$13,549
Average shares outstanding (Diluted)	2,667.9	2,671.6	2,669.2	2,674.0
Adjusted net earnings per share (Diluted)	\$2.59	\$2.48	\$5.26	\$5.07
Operational adjusted net earnings per share (Diluted)	\$2.75		\$5.50	

Notes:

¹ Acquisition, integration and divestiture related for the six months of 2021 primarily includes the gain on the divestiture of two Pharmaceutical brands outside of the U.S.

² European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company's previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance which is expected to be completed by the end of 2023.

³ COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's modification of its COVID-19 vaccine research program and manufacturing capacity to levels that meet all customer contractual requirements.

⁴ The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

Q2 QTD - Income Before Tax by Segment*
Dollars in Millions

	Consumer Health ¹		Pharmaceutical ¹		MedTech		Unallocated		Consumer Health Separation Costs		Worldwide Total	
	2022	2021	2022	2021	2022	2021	2022	2021	2022	2021	2022	2021
Reported Income Before Tax by Segment	\$ 784	866	4,420	4,294	1,141	1,746	(237)	(244)	(268)	-	5,840	6,662
% to Sales	20.6%	22.5%	33.2%	34.4%	16.5%	25.0%	-1.0%	-1.0%	-1.1%	0.0%	24.3%	28.6%
Intangible asset amortization expense	100	105	736	842	259	255	-	-	-	-	1,095	1,202
In-process research and development	-	-	-	-	-	-	-	-	-	-	-	-
Litigation related	78	122	36	(81)	271	(64)	-	-	-	-	385	(23)
Loss/(gain) on securities	-	(18)	102	(151)	7	(74)	-	-	-	-	109	(243)
Restructuring related	25	27	23	17	80	64	-	-	-	-	128	108
Acquisition, integration and divestiture related	-	-	-	-	-	14	-	-	-	-	-	14
Medical Device Regulation	-	-	-	-	70	56	-	-	-	-	70	56
COVID-19 Vaccine related costs	-	-	276	-	-	-	-	-	-	-	276	-
Consumer Health separation costs	-	-	-	-	-	-	-	-	268	-	268	-
Other	-	-	-	-	-	-	-	-	-	-	-	-
Adjusted Income Before Tax by Segment	\$ <u>987</u>	<u>1,102</u>	<u>5,593</u>	<u>4,921</u>	<u>1,828</u>	<u>1,997</u>	<u>(237)</u>	<u>(244)</u>	<u>-</u>	<u>-</u>	<u>8,171</u>	<u>7,776</u>
% to Sales	25.9%	28.6%	42.0%	39.4%	26.5%	28.6%	-1.0%	-1.0%	0.0%	0.0%	34.0%	33.4%

¹ Prior year income before tax has been reclassified as Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes

*Estimated as of 7/19/2022

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

Q2 YTD - Income Before Tax by Segment*
Dollars in Millions

	Consumer Health ¹		Pharmaceutical ¹		MedTech		Unallocated		Consumer Health Separation Costs		Worldwide Total	
	2022	2021	2022	2021	2022	2021	2022	2021	2022	2021	2022	2021
Reported Income Before Tax by Segment	\$ 1,470	1,708	8,344	9,463	2,618	3,375	(360)	(455)	(370)	-	11,702	14,091
% to Sales	19.9%	22.8%	31.9%	38.5%	18.9%	24.9%	-0.8%	-1.0%	-0.8%	0.0%	24.7%	30.9%
Intangible asset amortization expense	194	211	1,496	1,698	513	508	-	-	-	-	2,203	2,417
In-process research and development	-	-	610	-	-	-	-	-	-	-	610	-
Litigation related	78	122	36	(81)	271	(64)	-	-	-	-	385	(23)
Loss/(gain) on securities	0	(20)	496	(114)	24	(74)	-	-	-	-	520	(208)
Restructuring related	39	55	9	37	152	120	-	-	-	-	200	212
Acquisition, integration and divestiture related	-	-	-	(570)	-	46	-	-	-	-	-	(524)
Medical Device Regulation	-	-	-	-	130	102	-	-	-	-	130	102
COVID-19 Vaccine related costs	-	-	276	-	-	-	-	-	-	-	276	-
Consumer Health separation costs	-	-	-	-	-	-	-	-	370	-	370	-
Other	-	-	-	-	-	-	(7)	-	-	-	(7)	-
Adjusted Income Before Tax by Segment	\$ <u>1,781</u>	<u>2,076</u>	<u>11,267</u>	<u>10,433</u>	<u>3,708</u>	<u>4,013</u>	<u>(367)</u>	<u>(455)</u>	<u>-</u>	<u>-</u>	<u>16,389</u>	<u>16,067</u>
% to Sales	24.1%	27.7%	43.0%	42.4%	26.7%	29.6%	-0.8%	-1.0%	0.0%	0.0%	34.5%	35.2%

¹ Prior year income before tax has been reclassified as Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes

*Estimated as of 7/19/2022

Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
\$ in Millions

Quarter to Date

	Second Quarter July 3, 2022 GAAP	Intangible asset amortization	Litigation related	In-process research and development	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Medical Device Regulation	COVID-19 Vaccine Related Costs	Consumer Health separation costs	Consumer Health separation tax related costs	Tax legislation and other tax related	Other	Second Quarter July 3, 2022 Non-GAAP
Cost of products sold	\$ 7,919	(1,083)			(17)			(25)	(194)					6,600
Selling, marketing and admin expenses	6,226							(6)						6,220
Research and development expense	3,703							(39)	(110)					3,554
Other (Income) / Expense	273	(12)	(385)		(26)		(109)		28	(268)				(499)
In-process research and development	-													-
Restructuring	85				(85)									-
Provision for taxes on income	1,026	170	(29)		25		25	13	65	44	(2)	(78)		1,259
Net Earnings	4,814	925	414		103		84	57	211	224	2	78		6,912

	Second Quarter July 4, 2021 GAAP	Intangible asset amortization	Litigation related	In-process research and development	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Medical Device Regulation	COVID-19 Vaccine Related Costs	Consumer Health separation costs	Consumer Health separation tax related costs	Tax legislation and other tax related	Other	Second Quarter July 4, 2021 Non-GAAP
Cost of products sold	\$ 7,587	(1,202)			(20)			(20)						6,345
Selling, marketing and admin expenses	6,073							(6)						6,067
Research and development expense	3,394							(30)						3,364
Other (Income) / Expense	(488)		23		(32)		243							(268)
In-process research and development	-													-
Restructuring	56				(56)									-
Provision for taxes on income	384	163	(1)		17	3	(57)	10				632		1,151
Net Earnings	6,278	1,039	(22)		91	11	(186)	46				(632)		6,625

Year to Date

	Six Months July 3, 2022 GAAP	Intangible asset amortization	Litigation related	In-process research and development	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Medical Device Regulation	COVID-19 Vaccine Related Costs	Consumer Health separation costs	Consumer Health separation tax related costs	Tax legislation and other tax related	Other	Six Months July 3, 2022 Non-GAAP
Cost of products sold	\$ 15,517	(2,191)			(33)			(47)	(194)					13,052
Selling, marketing and admin expenses	12,164							(12)						12,152
Research and development expense	7,165							(71)	(110)					6,984
Other (Income) / Expense	171	(12)	(385)		(12)		(520)		28	(370)			7	(1,093)
In-process research and development	610			(610)										-
Restructuring	155				(155)									-
Provision for taxes on income	1,739	338	(82)	138	37		121	24	65	67	(98)	1	(2)	2,348
Net Earnings	9,963	1,865	467	472	163		399	106	211	303	98	(1)	(5)	14,041

	Six Months July 4, 2021 GAAP	Intangible asset amortization	Litigation related	In-process research and development	Restructuring related	Acquisition, integration and divestiture related (1)	(Loss)/gain on securities	Medical Device Regulation	COVID-19 Vaccine Related Costs	Consumer Health separation costs	Consumer Health separation tax related costs	Tax legislation and other tax related	Other	Six Months July 4, 2021 Non-GAAP
Cost of products sold	\$ 14,650	(2,417)			(47)			(37)						12,149
Selling, marketing and admin expenses	11,505							(11)						11,494
Research and development expense	6,572							(54)						6,518
Other (Income) / Expense	(1,370)		23		(56)	524	208							(671)
In-process research and development	-													-
Restructuring	109				(109)									-
Provision for taxes on income	1,616	340	(1)		37	(98)	(49)	19				654		2,518
Net Earnings	12,475	2,077	(22)		175	(426)	(159)	83				(654)		13,549

(1) 2021 primarily includes gains on the divestitures of two Pharmaceutical brands outside of the United States.